SCHEMBL14015355

SCHEMBL14015355

NCCNC(=O)CCNCCN(CCNCCC(=O)NCCN)CCNCCC(=O)NCCN

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.38
CYP2C9 P11712 1/20 0.38
KDM4A O75164 1/20 0.35
HIF1A Q16665 1/20 0.35
TET2 Q6N021 1/20 0.35
DOHH Q9BU89 1/20 0.35
CA12 O43570 3/20 0.33
CA6 P23280 3/20 0.33
CA7 P43166 3/20 0.33
CA9 Q16790 3/20 0.33
CA14 Q9ULX7 3/20 0.33
CA5B Q9Y2D0 3/20 0.33
MEN1 O00255 1/20 0.33
RECQL P46063 1/20 0.33
KMT2A Q03164 1/20 0.33
LMNA P02545 3/20 0.33
KDM4E B2RXH2 2/20 0.33
GAA P10253 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
DNM1 Q05193 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13813061 0.95 CYP2C9 (0.34) CYP2C19CYP2C9KDM4AHIF1ATET2
SCHEMBL16330324 0.90 DNM1 (0.33) KDM4AHIF1ATET2DOHHCA12
SCHEMBL10100177 0.88 CA12 (0.43) CYP2C19CYP2C9CA12CA6CA7
SCHEMBL14134895 0.87 DNM1 (0.31) KDM4AHIF1ATET2DOHHDNM1
SCHEMBL15963174 0.86 CA12 (0.48) CA12CA6CA7CA9CA14
SCHEMBL12219612 0.84 KDM4A (0.38) CYP2C19CYP2C9KDM4AHIF1ATET2
SCHEMBL13756030 0.83 FAAH (0.40) CYP2C19CYP2C9KDM4AHIF1ATET2
SCHEMBL14015341 0.83 DNM1 (0.35) CYP2C19KDM4AHIF1ATET2DOHH
SCHEMBL8239576 0.82 DNM1 (0.37) CYP2C19CYP2C9KDM4AHIF1ATET2
SCHEMBL13374199 0.82 KDM4A (0.36) CYP2C19CYP2C9KDM4AHIF1ATET2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080267903-A1 Cationic polyamines and dendrimeric polymers; anti-proliferative agents; for treatment of neoplasms and tumours, inflammatory disorders, autoimmune disorders, psoriasis, and atherosclerosis; gene therapy UNIVERSITY COLLEGE LONDON (GB) 2008-10-30 US disclosed
US-20080267903-A1 Cationic polyamines and dendrimeric polymers; anti-proliferative agents; for treatment of neoplasms and tumours, inflammatory disorders, autoimmune disorders, psoriasis, and atherosclerosis; gene therapy UNIVERSITY COLLEGE LONDON (GB) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080267903-A1 Cationic polyamines and dendrimeric polymers; anti-proliferative agents; for treatment of neoplasms and tumours, inflammatory disorders, autoimmune disorders, psoriasis, and atherosclerosis; gene therapy PCNA, SSB, PKD1 CYP2C19 4841/4885CYP2C9 4866/4885KDM4A 2860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.